Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin

Vilar, Fernando Crivelenti; Castro, Gleusa de; Moya, Maria Janete; Martinelli, Ana de Lourdes Candolo; Santis, Gil Cunha De; Cozac, Ana Paula Costa Nunes da Cunha; Figueiredo, José Fernando de Castro.
Rev. Soc. Bras. Med. Trop ; 40(6): 678-680, nov.-dez. 2007. tab
Artigo em Inglês | LILACS | ID: lil-471351

Documentos relacionados

  1. Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin.
  2. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
  3. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
  4. Possible role of IL-23 inhibitor in autoimmune hemolytic anemia.
  5. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
  6. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.
  7. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
  8. Autoimmune Cytopenias Are Highly Associated with Inborn Errors of Immunity and They May Be the Initial Presentations in Cases without Severe Infections.
  9. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
  10. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.